Story
Beijing, June 15, 2024 — Migrasome Therapeutics received first place and the Meiling Gold Award, the highest honor at the 11th Tsinghua University President’s Innovation Challenge. The company’s project was selected from 168 teams across healthcare, information technology, energy and environmental innovation, advanced manufacturing, education, culture and social innovation.
During the final, Dr. Chen Dai, Director of R&D, presented the project’s core strengths, technical features and development plan. The company’s engineered migrasome platform is being explored as a new delivery approach with potential applications in oncology, immune regulation and angiogenesis, with the aim of combining targeted delivery, flexible cargo loading and scalable production.
The judging panel examined the project’s innovation, technical barriers, business model and market need and provided recommendations for future development. The team views the award as recognition of both original migrasome science and its translational potential.
The company plans to continue fundamental research and technology development with industry partners.